In:
Journal of Drug Delivery and Therapeutics, Society of Pharmaceutical Tecnocrats, Vol. 11, No. 4-S ( 2021-08-15), p. 263-270
Kurzfassung:
The coronavirus disease 2019 (COVID-19) pandemic has highlighted the urgent need for efficient SARS coronavirus 2 (SARS-CoV-2) preventative vaccines to limit the burden and spread of SARS-CoV-2 in humans. Intranasal immunization is a promising technique for preventing COVID-19 because the nasal mucosa acts as a first line of defense against SARS-CoV-2 entrance before the virus spreads to the lungs. Nasal vaccination has many advantages over traditional vaccine administration methods. These include the simplicity of administration without the use of needles, which decreases the risks of needle stick injuries and disposal. This channel also provides simple access to a crucial portion of the immune system that can stimulate other mucosal sites throughout the body. By targeting immunoglobulin A (IgA), antibodies found only in the mucosa, an intranasal vaccination would elicit immunological responses in the nose, throat, and lungs. Potential pathogens are trapped by the mucosa, which acts as a physical barrier to prevent them from entering the body. Given this, the intranasal vaccine would prevent virus transmission via exhaled droplets or aerosols because there would be no virus in the body to expel .There are several intranasal vaccines for protection against sars-cov2 are under preclinical and clinical trials .The key challenge is in Designing delivery strategies that take into account the wide range of diseases, populations, and healthcare delivery settings that stand to benefit from this unique mucosal route should be prioritized. Keywords: COVID-19, Intranasal vaccine, Immunoglobulin A, Permeation
Materialart:
Online-Ressource
ISSN:
2250-1177
DOI:
10.22270/jddt.v11i4-S.4942
Sprache:
Unbekannt
Verlag:
Society of Pharmaceutical Tecnocrats
Publikationsdatum:
2021
ZDB Id:
2767921-4
SSG:
15,3
Permalink
